TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06599021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscular strengthening training
Description: 6 weeks daily muscular strengthening training.
Study: NCT06450366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for Ezetimibe
Description: Administered orally.
Study: NCT06599021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skill-based training
Description: 15 sessions skill based swallowing training lead by a speech and language pathologist during 3 weeks.
Study: NCT06600685

Intervention type: OTHER
Group type: OTHER
Intervention: Functionally oriented music therapy (FMT)
Description: There are different methods of music therapy and one of these is FMT. It is a body-based and music therapeutic treatment method that is used for health-promoting purposes. With the help of i.e. drums, cymbals, various custom-made drumsticks, flutes, chairs, balance balls and balance cushions. FMT strives to support, strengthen and develop the person's physical, mental and social abilities. FMT-sessions (20 minuets/1 time a week) are performed individuelly (a patient with a educated music therapist).
Study: NCT06601387

Intervention type: PROCEDURE
Group type: OTHER
Intervention: choledochoduodonostomy
Description: surgical drainage procedures
Study: NCT05057793

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: geko
Description: The geko device will be self-administered and deliver 12 hours of therapy daily.
Study: NCT05774652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention Dietary advise and/or advise on physical activity
Description: Lifestyle intervention Dietary advise and/or advise on physical activity
Study: NCT06112834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBV A/B
Description: Recombinant Botulinum Vaccine A/B, rBV A/B
Study: NCT06601387

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hepaticojejunostomy
Description: surgical intervention
Study: NCT04886739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGB-400
Description: Topical gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Topical gel
Study: NCT06611176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local levobupivacaine
Description: submucosal injection of levobupivacaine during esophageal esad
Study: NCT06609863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dTACE-HAIC
Description: dTACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then drug-eluting microspheres were used (100-300um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2. Hepatic arterial infusion chemotherapy administration of oxaliplatin, fluorouracil, and leucovorin via the tumor feeding arteries every 4 weeks
Study: NCT04741607

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement (BLX implant system, Straumann, Basel, Switzerland)
Description: Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement (BLX implant system, Straumann, Basel, Switzerland)
Description: Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland)
Description: Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland)
Description: Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).
Study: NCT05286541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateralized buccal cortex with xenograft
Description: the buccal cortex of the deficient ridge was separated and lateralized then fixed at the desired distance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateralized buccal cortex with autogenous particulate
Description: lateralized buccal cortex with autogenous particulate
Study: NCT05328700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Perform a neuromuscular bandage with kinesiotape in patients with plantar fasciitis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tape
Description: Perform a neuromuscular bandage with tape (Hipofix(R)) in patients with plantar fasciitis
Study: NCT05757037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz\].

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: laser acupuncture
Description: a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz\].
Study: NCT06267183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SV001
Description: SV001 ： single-dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ： single-dose
Study: NCT05529368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Exercise and Tai Chi Exercise interventions
Description: Subjects diagnosed with IAD were randomly assigned to the exercise group, the tai chi group, or the control group. The exercise group and tai chi group received conventional exercise and tai chi for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Exercise and Tai Chi Exercise interventions
Description: Subjects diagnosed with IAD were randomly assigned to the exercise group, the tai chi group, or the control group. The exercise group and tai chi group received conventional exercise and tai chi for 8 weeks.
Study: NCT05925725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: • harpagozid • boswellin = LOXACON
Description: Exercise therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: • harpagozid • boswellin = LOXACON
Description: Exercise therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: • harpagozid • boswellin = LOXACON
Description: Exercise therapy
Study: NCT04741607

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland)
Description: The occlusal aspect of the grafted socket in the delayed implant placement/control group is closed with a collagen matrix.
Study: NCT06135480

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: subcision ,PRP or saline and microneedling
Description: minimally invasive procedures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: subcision ,PRP or saline and microneedling
Description: minimally invasive procedures
Study: NCT05557370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papilloma Virus vaccine (GARDASIL 9)
Description: Patients will be scheduled to receive 3-dose 9vHPV vaccination (vaccination at enrollment \[time 0\], 2 months \[+ 6 weeks\], and 6 months \[+ 6 weeks\] per standard guidelines).
Study: NCT05531682

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive several injections of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0017
Description: Subjects will receive HB0017 in different dosing regimens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0017
Description: Subjects will receive HB0017 in different dosing regimens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0017
Description: Subjects will receive HB0017 in different dosing regimens
Study: NCT04608630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab 60 MG/ML
Description: Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid 5Mg/Bag 100Ml Inj
Description: Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride or 5% Dextrose, administered via intravenous infusion over at least 15 minutes on Study Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% or 5% Dextrose Intravenous
Description: Patients allocated to the placebo arm and Denosumab arm will receive 0.9% Sodium Chloride or 5% Dextrose 100ml administered via intravenous infusion over at least 15 minutes on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% or 5% Dextrose Intravenous
Description: Patients allocated to the placebo arm and Denosumab arm will receive 0.9% Sodium Chloride or 5% Dextrose 100ml administered via intravenous infusion over at least 15 minutes on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Injection
Description: Patients allocated to the placebo arm and Zoledronic acid arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% Injection
Description: Patients allocated to the placebo arm and Zoledronic acid arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180
Study: NCT04315324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKR1C3-activated Prodrug OBI-3424
Description: Given IV
Study: NCT05427045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home - exercise program
Description: Home exercise program
Study: NCT04889222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00050
Description: Noninvasive pulse oximeter sensor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD SET SpO2
Description: Noninvasive pulse oximeter sensor
Study: NCT04977921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lab session
Description: assign students to clinical modules for study the clinical lab scope of practice
Study: NCT04709354

Intervention type: DIAGNOSTIC_TEST
Intervention: Dermoscopic examination
Description: The periungual area, nail plate, subungual area of the patients' fingernails will be examined and images of the lesional nails or target nails will be recorded for comparison.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dermoscopic examination
Description: The periungual area, nail plate, subungual area of the patients' fingernails will be examined and images of the lesional nails or target nails will be recorded for comparison.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dermoscopic examination
Description: The periungual area, nail plate, subungual area of the patients' fingernails will be examined and images of the lesional nails or target nails will be recorded for comparison.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dermoscopic examination
Description: The periungual area, nail plate, subungual area of the patients' fingernails will be examined and images of the lesional nails or target nails will be recorded for comparison.
Study: NCT04987268

Intervention type: GENETIC
Intervention: clonal hematopoiesis of indeterminate potential
Description: Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)

Intervention type: GENETIC
Intervention: clonal hematopoiesis of indeterminate potential
Description: Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)
Study: NCT04355572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 4000IU daily
Description: Randomized to receive vitamin D 4000IU daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized to placebo daily
Study: NCT05317195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-1
Description: NP-1; 8.4 mg nicotine; pH 8.0; moisture 30

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-1
Description: NP-1; 8.4 mg nicotine; pH 8.0; moisture 30

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-1
Description: NP-1; 8.4 mg nicotine; pH 8.0; moisture 30

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-1
Description: NP-1; 8.4 mg nicotine; pH 8.0; moisture 30

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP-1
Description: NP-1; 8.4 mg nicotine; pH 8.0; moisture 30

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP-1
Description: NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
Study: NCT06450366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for Bempedoic Acid
Description: Administered orally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Bempedoic Acid
Description: Administered orally.
Study: NCT05325632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 pulsed DC1
Description: Vaccine will be administered weekly for 6 weeks. Boosters will be given at months 6, 9 and 12.
Study: NCT05317195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-2
Description: NP-2; 8.4 mg nicotine; pH 9.0; moisture 30

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-2
Description: NP-2; 8.4 mg nicotine; pH 9.0; moisture 30

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-2
Description: NP-2; 8.4 mg nicotine; pH 9.0; moisture 30

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-2
Description: NP-2; 8.4 mg nicotine; pH 9.0; moisture 30

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP-2
Description: NP-2; 8.4 mg nicotine; pH 9.0; moisture 30

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP-2
Description: NP-2; 8.4 mg nicotine; pH 9.0; moisture 30

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-3
Description: NP-3; 3.6 mg nicotine; pH 8.0; moisture 15

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-3
Description: NP-3; 3.6 mg nicotine; pH 8.0; moisture 15

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-3
Description: NP-3; 3.6 mg nicotine; pH 8.0; moisture 15

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-3
Description: NP-3; 3.6 mg nicotine; pH 8.0; moisture 15

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP-3
Description: NP-3; 3.6 mg nicotine; pH 8.0; moisture 15

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP-3
Description: NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
Study: NCT06361940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors or tamoxifen
Description: Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status.
Study: NCT06617689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Various levels of patient education
Description: The three interventions:~GROUP BASED TEACHING In groups of 8-12 patients, 30 minutes of standardised teaching is given. The teaching focuses in particular on the changes in diet and the impact this has on oral pH, enamel erosion and caries; recommended oral hygiene; and good drinking habits.~WEBSITE Website providing recommendations for oral hygiene and drinking habits, as well as in depth information on the topic.~DENTAL HYGIENE SAMPLES These are samples relevant for maintaining proper oral hygiene, distributed free, together with a description of how to use them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Various levels of patient education
Description: The three interventions:~GROUP BASED TEACHING In groups of 8-12 patients, 30 minutes of standardised teaching is given. The teaching focuses in particular on the changes in diet and the impact this has on oral pH, enamel erosion and caries; recommended oral hygiene; and good drinking habits.~WEBSITE Website providing recommendations for oral hygiene and drinking habits, as well as in depth information on the topic.~DENTAL HYGIENE SAMPLES These are samples relevant for maintaining proper oral hygiene, distributed free, together with a description of how to use them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Various levels of patient education
Description: The three interventions:~GROUP BASED TEACHING In groups of 8-12 patients, 30 minutes of standardised teaching is given. The teaching focuses in particular on the changes in diet and the impact this has on oral pH, enamel erosion and caries; recommended oral hygiene; and good drinking habits.~WEBSITE Website providing recommendations for oral hygiene and drinking habits, as well as in depth information on the topic.~DENTAL HYGIENE SAMPLES These are samples relevant for maintaining proper oral hygiene, distributed free, together with a description of how to use them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Various levels of patient education
Description: The three interventions:~GROUP BASED TEACHING In groups of 8-12 patients, 30 minutes of standardised teaching is given. The teaching focuses in particular on the changes in diet and the impact this has on oral pH, enamel erosion and caries; recommended oral hygiene; and good drinking habits.~WEBSITE Website providing recommendations for oral hygiene and drinking habits, as well as in depth information on the topic.~DENTAL HYGIENE SAMPLES These are samples relevant for maintaining proper oral hygiene, distributed free, together with a description of how to use them.
Study: NCT05317195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-4
Description: NP-4; 3.6 mg nicotine; pH 8.0; moisture 30

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-4
Description: NP-4; 3.6 mg nicotine; pH 8.0; moisture 30

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-4
Description: NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
Study: NCT04466566

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will serve as the control
Study: NCT05348122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103,Q2W
Description: TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103,Q2W
Description: TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
Study: NCT04987268

Intervention type: GENETIC
Intervention: clonal hematopoiesis of indeterminate potential
Description: Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)
Study: NCT06235333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling Disorder Screening Day screener
Description: See descriptions
Study: NCT05348122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103,QW
Description: TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Study: NCT04466566

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39
Description: Exendin-9,39 will block the GLP-1 receptor
Study: NCT06235333

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gambling Disorder Screening Day information sheet
Description: See descriptions
Study: NCT06333093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare
Description: Two (2) cold snare resections of the duodenal mucosa during an already scheduled upper gastrointestinal interventional endoscopy under deep sedation (propofol).
Study: NCT06345131

Intervention type: OTHER
Group type: OTHER
Intervention: Non invasive blood pressure monitoring
Description: Non invasive blood pressure monitoring

Intervention type: OTHER
Group type: OTHER
Intervention: Non invasive blood pressure monitoring
Description: Non invasive blood pressure monitoring

Intervention type: OTHER
Group type: OTHER
Intervention: Non invasive blood pressure monitoring
Description: Non invasive blood pressure monitoring
Study: NCT05471232

Intervention type: GENETIC
Intervention: Genomic sequencing and molecular diagnostic results, if any.
Description: Genomic sequencing results may be used for diagnosis and treatment of participants.

Intervention type: OTHER
Intervention: EHR-Based Network Model
Description: EHR-based network will be created to predict psychiatric outcomes in youth with IDDs
Study: NCT05325632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 pulsed DC1
Description: Vaccine will be administered weekly for 6 weeks. Boosters will be given at months 6, 9 and 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 pulsed DC1
Description: Vaccine will be administered weekly for 6 weeks. Boosters will be given at months 6, 9 and 12.
Study: NCT06364137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleo
Description: Therapist-led psychotherapy sessions implemented within the Teleo virtual therapy platform.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard videoconferencing
Description: Therapist-led psychotherapy sessions implemented in standard (non-Teleo) video platform
Study: NCT06678516

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: Participants are asked to abstain from any form of fasting or calorie restriction in one month of the study (which is also a pre-fasting washout for those volunteers that might be performing forms of fasting before the study) and then start with one month of intermittent fasting, with daily fasting duration from 7:30 to 18:30. Food is abstained from during fasting, only water and zero-calorie drinks like black coffee and unsweetened tea are allowed.
Study: NCT06614686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U87 autologous CAR T-cell
Description: Treatment with U87 chimeric antigen receptor T-cell infusion.